Tradestie Institutional Equity Comparison Engine

CRVS vs RGNX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRVS Overall Edge

CRVS Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Corvus Pharmaceuticals, Inc. (CRVS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while RGNX counters with relative strength in Valuation. Fundamentally, CRVS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus RGNX at N/M Forward P/E and -120.4% operating margin (-69.2% YoY). In options structure, CRVS sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RGNX
CRVS N/M vs RGNX N/M Fwd P/E
Growth & Margin Winner CRVS
Op Margin 0.0% vs -120.4% ยท YoY +0.0% vs -69.2%
Momentum & Technical Winner CRVS
1Y +32.9% vs -36.0% ยท 52W Pos 21% vs 19%
Options & Structure Winner CRVS
BREAKDOWN (8th %ile IV) vs BREAKDOWN (52nd %ile IV)
CRVS NASDAQ
Corvus Pharmaceuticals, Inc.
Pharmaceutical Preparations
$10.63
-0.05% 1D
Market Cap $895.8M
1M Return +11.71%
1Y Return +32.94%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 20.0 Fund 46.0 Flow 72.0 Mom 50.0
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
1M Return +7.58%
1Y Return -36.0%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRVS +32.94% RGNX -36.0% Spread: +68.94 pp (CRVS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRVS TTM Op. Margin: 0.0% RGNX TTM Op. Margin: -120.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRVS vs RGNX. Trailing 12-month operating profitability (CRVS 0.0% vs RGNX -120.4%) and valuation multiples (CRVS N/M vs RGNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRVS (7) vs RGNX (1)
Institutional Metric CRVS RGNX Criterion Row Winner
Market Capitalization Scale $895.8M $500.9M Larger Scale CRVS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -69.2% Higher Growth CRVS
Operating Margin (TTM) Profitability 0.0% -120.4% Higher Margin CRVS
Net Profit Margin Profitability 0.0% -113.9% Higher Margin CRVS
Return on Equity (ROE) Capital Efficiency -45.9% -113.2% Higher ROE CRVS
52-Week Range Position Momentum 21% ($6โ€“$27) 19% ($5โ€“$16) Stronger Trend CRVS
Beta / 30D Volatility Risk Regime 1.87ฮฒ ยท 71% Vol 1.82ฮฒ ยท 76% Vol Lower Realized Risk CRVS
Unified Institutional Score Composite Signal 34.3 / 100 (SELL) 45.3 / 100 (HOLD) Higher Composite RGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRVS vs RGNX Buy Guide
CRVS BREAKDOWN
91d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live CRVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRVS nor RGNX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.